Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity

v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance at Dec. 31, 2020 $ (1,979) $ 6 $ 144,156 $ (145,803) $ (338)
Beginning balance (in shares) at Dec. 31, 2020   56,371,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 70   70    
Exercise of stock options, net of vesting of restricted shares (in shares)   131,000      
Release of restricted stock (in shares)   1,012,000      
Issuance of common stock for payment of board of director fees 66   66    
Issuance of common stock for payment of board of director fees (in shares)   99,000      
Sales of common stock, net of issuance costs 30,537 $ 1 30,536    
Sales of common stock, net of issuance costs (in shares)   15,123,000      
Stock-based compensation expense 2,426   2,426    
Cumulative translation adjustment 15       15
Net income (loss) (22,083)     (22,083)  
Ending balance at Jun. 30, 2021 9,052 $ 7 177,254 (167,886) (323)
Ending balance (in shares) at Jun. 30, 2021   72,736,000      
Beginning balance at Mar. 31, 2021 14,615 $ 7 175,046 (160,110) (328)
Beginning balance (in shares) at Mar. 31, 2021   71,204,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 5   5    
Exercise of stock options, net of vesting of restricted shares (in shares)   11,000      
Release of restricted stock (in shares)   829,000      
Sales of common stock, net of issuance costs 832   832    
Sales of common stock, net of issuance costs (in shares)   692,000      
Stock-based compensation expense 1,371   1,371    
Cumulative translation adjustment 5       5
Net income (loss) (7,776)     (7,776)  
Ending balance at Jun. 30, 2021 9,052 $ 7 177,254 (167,886) (323)
Ending balance (in shares) at Jun. 30, 2021   72,736,000      
Beginning balance at Dec. 31, 2021 $ 65,277 $ 10 264,944 (199,325) (352)
Beginning balance (in shares) at Dec. 31, 2021 96,751,610 96,752,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares $ 16   16    
Exercise of stock options, net of vesting of restricted shares (in shares) 22,757 23,000      
Release of restricted stock (in shares)   882,000      
Issuance of common stock under the 2018 employee stock purchase plan $ 116   116    
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000      
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 1,125   1,125    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   384,000      
Stock-based compensation expense 1,264   1,264    
Cumulative translation adjustment (117)       (117)
Net income (loss) (31,988)     (31,988)  
Ending balance at Jun. 30, 2022 $ 35,693 $ 10 267,465 (231,313) (469)
Ending balance (in shares) at Jun. 30, 2022 98,137,070 98,137,000      
Beginning balance at Mar. 31, 2022 $ 51,990 $ 10 266,606 (214,242) (384)
Beginning balance (in shares) at Mar. 31, 2022   97,251,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Release of restricted stock (in shares)   790,000      
Issuance of common stock under the 2018 employee stock purchase plan 116   116    
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000      
Stock-based compensation expense 743   743    
Cumulative translation adjustment (85)       (85)
Net income (loss) (17,071)     (17,071)  
Ending balance at Jun. 30, 2022 $ 35,693 $ 10 $ 267,465 $ (231,313) $ (469)
Ending balance (in shares) at Jun. 30, 2022 98,137,070 98,137,000